Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNeuphoria Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$0.56 | -$0.56 | -$0.56 |
| Q2 2026 | 1 | -$0.56 | -$0.56 | -$0.56 |
| Q3 2026 | 1 | -$1.58 | -$1.58 | -$1.58 |
| Q4 2026 | 1 | -$1.64 | -$1.64 | -$1.64 |
| Q1 2027 | 1 | -$1.14 | -$1.14 | -$1.14 |
| Q2 2027 | 1 | -$1.18 | -$1.18 | -$1.18 |
Neuphoria Therapeutics Inc. Earnings Date And Information
Neuphoria Therapeutics Inc. last posted its earnings results on Friday, May 15th, 2026. The company reported $-0.09 earnings per share for the quarter, topping analysts' consensus estimates of $-0.56 by $0.47. The company had revenue of 0 for the quarter and had revenue of 15.65 M for the year. Neuphoria Therapeutics Inc. has generated $0 earnings per share over the last year ($-0.23 diluted earnings per share) and currently has a price-to-earnings ratio of -0.4. Neuphoria Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Neuphoria Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/15/2026 | Q3 2026 | -$0.56 | -$0.09 | 0.47 | $0 | $0 |
| 02/17/2026 | Q2 2026 | -$0.56 | $0.41 | 0.97 | $0 | $0 |
| 11/14/2025 | Q1 2026 | -$0.55 | -$6.67 | -6.12 | $0 | $0 |
| 09/29/2025 | Q4 2025 | -$0.56 | -$4.65 | -4.09 | $15.00 M | $-10,472,445 |
| 05/20/2025 | Q3 2025 | -$0.47 | $6.55 | 7.02 | $15.00 M | $25.05 M |
| 02/14/2025 | Q2 2025 | N/A | -$0.01 | N/A | N/A | $1.07 M |
| 11/14/2024 | Q1 2025 | N/A | -$0.00 | N/A | $264.30 K | $0 |
| 09/30/2024 | Q4 2024 | -$11.38 | -$0.00 | 11.38 | $264.30 K | $0 |
| 03/30/2024 | Q3 2024 | N/A | -$0.03 | N/A | $264.30 K | $0 |
| 12/31/2023 | Q2 2024 | N/A | -$0.05 | N/A | N/A | $0 |
| 09/30/2023 | Q1 2024 | -$13.44 | -$0.04 | 13.4 | N/A | $0 |
| 10/18/2023 | Q4 2023 | N/A | -$0.00 | N/A | N/A | $-44,058 |
| 03/31/2023 | Q3 2023 | N/A | -$0.00 | N/A | N/A | $-44,717 |
| 12/31/2022 | Q2 2023 | N/A | -$0.00 | N/A | N/A | $45.37 K |
| 09/30/2022 | Q1 2023 | N/A | -$0.00 | N/A | N/A | $43.02 K |
| 10/14/2022 | Q4 2022 | N/A | -$0.00 | N/A | N/A | $2.02 M |
| 03/31/2022 | Q3 2022 | N/A | -$0.00 | N/A | N/A | $2.21 M |
| 12/31/2021 | Q2 2022 | N/A | -$0.00 | N/A | N/A | $61.38 K |
| 09/30/2021 | Q1 2022 | N/A | -$0.00 | N/A | N/A | $61.28 K |
| 06/30/2021 | Q4 2021 | N/A | -$0.00 | N/A | N/A | $121.25 K |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Neuphoria Therapeutics Inc. Earnings: FAQ's
In the previous quarter, Neuphoria Therapeutics Inc. (:NEUP) reported $-0.09 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.56 by $0.47.
The conference call for Neuphoria Therapeutics Inc.'s latest earnings report can be listened to online.
The conference call transcript for Neuphoria Therapeutics Inc.'s latest earnings report can be read online.
Neuphoria Therapeutics Inc. (:NEUP) has a recorded annual revenue of $15.65 M.
Neuphoria Therapeutics Inc. (:NEUP) has a recorded net income of $-369,632.Neuphoria Therapeutics Inc. has generated $-0.23 earnings per share over the last four quarters.
Neuphoria Therapeutics Inc. (:NEUP) has a price-to-earnings ratio of -0.4 and price/earnings-to-growth ratio is 0.01.